rilotumumab rilotumumab rilotumumab (previously amg102) is a human monoclonal antibody designed for the treatment of solid tumors. rilotumumabmonoclonal antibodytypewhole antibodysourcehumantargethgfclinical dataatc codenoneidentifierscas number872514-65-3 nchemspidernoneunii51wew898ijkeggd09659chemical and physical dataformulac6464h9932n1708o2010s46molar mass145207.27 g·mol−1 ny (what is this?) (verify) rilotumumab was in development by amgen, inc. until in november 2014, when amgen announced it had halted all clinical trials of the compound in advanced gastric cancer (including two phase iii studies) after one of the trials found an increase in the number of deaths in those who were taking rilotumumab and chemotherapy when compared to those who were only administered chemotherapy.